Synthetic Biologics Inc (NYSEMKT:SYN) announced its earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.03, Bloomberg Earnings reports.

Synthetic Biologics (NYSEMKT SYN) traded up 16.3269% during mid-day trading on Friday, hitting $0.6049. 2,786,664 shares of the company traded hands. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $0.64. The firm’s market capitalization is $73.73 million. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.90.

A number of brokerages have issued reports on SYN. ValuEngine lowered shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research lowered shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Friday, April 7th. Finally, William Blair restated an “outperform” rating and set a $5.00 target price on shares of Synthetic Biologics in a research report on Monday, May 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. Synthetic Biologics has an average rating of “Hold” and an average target price of $4.46.

TRADEMARK VIOLATION WARNING: “Synthetic Biologics Inc (NYSEMKT:SYN) Posts Earnings Results” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/04/synthetic-biologics-inc-nysemktsyn-posts-earnings-results.html.

A number of institutional investors have recently added to or reduced their stakes in the company. Creative Planning boosted its position in Synthetic Biologics by 65.4% in the second quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after buying an additional 70,000 shares in the last quarter. UBS Group AG boosted its position in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after buying an additional 20,038 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after buying an additional 7,962 shares in the last quarter. LMR Partners LLP bought a new position in Synthetic Biologics during the second quarter worth approximately $194,000. Finally, Norges Bank bought a new position in Synthetic Biologics during the fourth quarter worth approximately $356,000.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Earnings History for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.